Nektar Therapeutics
NKTR
240 hedge funds and large institutions have $3.01B invested in Nektar Therapeutics in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 73 increasing their positions, 81 reducing their positions, and 25 closing their positions.
272% more call options, than puts
Call options by funds: $28.1M | Put options by funds: $7.56M
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
5% more capital invested
Capital invested by funds: $2.88B → $3.01B (+$131M)
0% more funds holding
Funds holding: 239 → 240 (+1)
0.07% less ownership
Funds ownership: 6.15% → 6.08% (-0.07%)
10% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 81
Top Buyers
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$8.67M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.45M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.09M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$7.91M |
| 5 |
Morgan Stanley
New York
|
+$6.23M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.5M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$8.49M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.21M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$6.1M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.52M |
NKTR Hedge Fund Activity: Q3 2021 in Review
240 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2021, worth a combined $3.01B — up 4.5% from $2.88B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NKTR positions and 25 closed out — a net gain of 3 holders — while 73 added to existing stakes and 81 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $8.67M. The largest seller was Fidelity Investments, cutting an estimated $29.5M.
- 240 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2021, up from 239 in Q2 2021.
- Funds reported $3.01B of Nektar Therapeutics stock for Q3 2021, up 4.5% quarter-over-quarter.
- 28 funds opened new Nektar Therapeutics positions in Q3 2021 and 25 closed out, a net change of +3 holders.
- The largest Nektar Therapeutics buyer in Q3 2021 was First Trust Advisors, an estimated $8.67M added.
- The largest Nektar Therapeutics seller in Q3 2021 was Fidelity Investments, an estimated $29.5M sold.
Based on aggregated 13F filings for Q3 2021.